1. Targeting BRAF-mutant non-small cell lung cancer: Current status and future directions.
- Author
-
Riudavets, Mariona, Cascetta, Priscilla, and Planchard, David
- Subjects
- *
NON-small-cell lung carcinoma , *IMMUNE checkpoint inhibitors - Abstract
• Vemurafenib and dabrafenib showed relevant clinical activity in pre-treated NSCLC with BRAF V600E mutations • Dabrafenib/trametinib demonstrated its superiority in pre-treated and treatment-naïve BRAF V600E-mutant NSCLC • Available efficacy data on BRAF V600 non-E mutations suggests a comparable efficacy of BRAF/MEK inhibitors • Limited activity of BRAF/MEK inhibitors has been observed in BRAF non-V600E mutations Lung cancer harbouring BRAF mutations accounts for 4% of all non-small cell lung cancer (NSCLC) cases, identifying a relevant subset of patients that need to be promptly managed. Three subtypes of BRAF mutations have been described: class I (V600E), and class II and III (non-V600), with different prognostic and predictive outcomes. Pivotal phase II trials have demonstrated the efficacy of the double BRAF/MEK inhibition with dabrafenib plus trametinib in patients harbouring V600E mutations, making BRAF a mandatory requirement in the genetic portrait of advanced non-squamous lung cancer patients. However, non-V600 mutations represent around 50% of BRAF -mutant NSCLC patients, for which no specific targeted approaches are approved. A paradigm shift from the double BRAF/MEK inhibition to combinations with agents with distinct mechanisms of action, such as immune-checkpoint inhibitors, pan-RAF and selective ERK 1/2 inhibitors, is under investigation and may change the therapeutic landscape of BRAF -driven NSCLC. This paper provides a practical, concise and updated review on the therapeutic strategies in NSCLC with BRAF mutations. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF